Favorable Outcomes in Severe Aplastic Anemia Patients Undergoing Allo-HSCT with Fludarabine, Cyclophosphamide, and ATG Conditioning

Matched sibling donor (MSD) allogenic stem cell transplantation (allo-HSCT) is the standard of care curative treatment for young, fit patients with severe aplastic anemia (SAA). Several conditioning regimens have been studied, with Fludarabine (Flu)/Cyclophosphamide (Cy)/Anti-thymocyte globulin (ATG) or Cy/ATG demonstrating the best survival outcomes. Previous research reported 5-year survival probabilities of 91% for Flu/Cy/ATG, 91% for Cy/ATG, 80% for Cy ± Flu, and 84% for Bu/Cy (Bejanyan et al., 2019).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Reem Alasbali, Riad El Fakih, Ahmed Kotb Abdrabou, Naeem Chaudhri, Saud Alhayli, Fahad Alsharif, Amr Hanbali, Feras Alfraih, Marwan Shaheen, Mansour Alfayez, Alfadel Alshaibani, Abdulwahab Albabtain, Ahmad Alotaibi, AymanTusneem A SaadElhassan, Hadeel Sam Tags: 208 Source Type: research